APA

Koda R. T., Garcia A. A., Chatterjee D. J., Li W. Y., Parimoo D., Jeffers S., Rogers M., Leichman C. G., Leichman L., Wu E. Y., Shetty B. V., Webber S., Clendinnin N. & Muggia F. M. (19990520). Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors. : Cancer chemotherapy and pharmacology.

Chicago

Koda R T, Garcia A A, Chatterjee D J, Li W Y, Parimoo D, Jeffers S, Rogers M, Leichman C G, Leichman L, Wu E Y, Shetty B V, Webber S, Clendinnin N and Muggia F M. 19990520. Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors. : Cancer chemotherapy and pharmacology.

Harvard

Koda R. T., Garcia A. A., Chatterjee D. J., Li W. Y., Parimoo D., Jeffers S., Rogers M., Leichman C. G., Leichman L., Wu E. Y., Shetty B. V., Webber S., Clendinnin N. and Muggia F. M. (19990520). Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors. : Cancer chemotherapy and pharmacology.

MLA

Koda R T, Garcia A A, Chatterjee D J, Li W Y, Parimoo D, Jeffers S, Rogers M, Leichman C G, Leichman L, Wu E Y, Shetty B V, Webber S, Clendinnin N and Muggia F M. Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors. : Cancer chemotherapy and pharmacology. 19990520.